Geode Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,060,417
| Closed | -$40.7M | – | 4852 |
|
|
2023
Q2 | $40.7M | Buy |
1,060,417
+111,866
| +12% | +$2.87M | ﹤0.01% | 1389 |
|
|
2023
Q1 | $22M | Buy |
948,551
+34,325
| +4% | +$818K | ﹤0.01% | 1735 |
|
|
2022
Q4 | $24M | Buy |
914,226
+39,669
| +5% | +$879K | ﹤0.01% | 1653 |
|
|
2022
Q3 | $17.2M | Buy |
874,557
+44,483
| +5% | +$892K | ﹤0.01% | 1848 |
|
|
2022
Q2 | $14.5M | Buy |
830,074
+53,008
| +7% | +$832K | ﹤0.01% | 1991 |
|
|
2022
Q1 | $12.7M | Buy |
777,066
+43,409
| +6% | +$590K | ﹤0.01% | 2183 |
|
|
2021
Q4 | $12M | Buy |
733,657
+113,888
| +18% | +$1.62M | ﹤0.01% | 2330 |
|
|
2021
Q3 | $7.91M | Buy |
619,769
+1,063
| +0.2% | +$14K | ﹤0.01% | 2637 |
|
|
2021
Q2 | $8.74M | Buy |
618,706
+172,669
| +39% | +$2.76M | ﹤0.01% | 2554 |
|
|
2021
Q1 | $6.93M | Buy |
446,037
+35,817
| +9% | +$584K | ﹤0.01% | 2609 |
|
|
2020
Q4 | $6.51M | Buy |
410,220
+229,629
| +127% | +$3.46M | ﹤0.01% | 2449 |
|
|
2020
Q3 | $2.19M | Sell |
180,591
-2,151
| -1% | -$28.8K | ﹤0.01% | 2832 |
|
|
2020
Q2 | $2.11M | Buy |
182,742
+1,341
| +0.7% | +$18.5K | ﹤0.01% | 2808 |
|
|
2020
Q1 | $2.48M | Buy |
181,401
+7,864
| +5% | +$93K | ﹤0.01% | 2565 |
|
|
2019
Q4 | $1.02M | Buy |
173,537
+20,961
| +14% | +$114K | ﹤0.01% | 3271 |
|
|
2019
Q3 | $808K | Buy |
152,576
+441
| +0.3% | +$2.93K | ﹤0.01% | 3307 |
|
|
2019
Q2 | $1.17M | Buy |
152,135
+7,325
| +5% | +$112K | ﹤0.01% | 3187 |
|
|
2019
Q1 | $2.88M | Buy |
144,810
+19,331
| +15% | +$337K | ﹤0.01% | 2629 |
|
|
2018
Q4 | $1.66M | Buy |
125,479
+12,689
| +11% | +$253K | ﹤0.01% | 2866 |
|
|
2018
Q3 | $4.14M | Buy |
112,790
+12,525
| +12% | +$402K | ﹤0.01% | 2468 |
|
|
2018
Q2 | $3.51M | Buy |
100,265
+19,477
| +24% | +$747K | ﹤0.01% | 2534 |
|
|
2018
Q1 | $3.76M | Buy |
80,788
+9,657
| +14% | +$353K | ﹤0.01% | 2419 |
|
|
2017
Q4 | $2.67M | Buy |
71,131
+7,872
| +12% | +$344K | ﹤0.01% | 2603 |
|
|
2017
Q3 | $3.37M | Buy |
63,259
+4,975
| +9% | +$296K | ﹤0.01% | 2442 |
|
|
2017
Q2 | $3.32M | Buy |
58,284
+5,722
| +11% | +$287K | ﹤0.01% | 2429 |
|
|
2017
Q1 | $2.83M | Buy |
52,562
+2,989
| +6% | +$169K | ﹤0.01% | 2458 |
|
|
2016
Q4 | $2.83M | Buy |
49,573
+5,094
| +11% | +$308K | ﹤0.01% | 2427 |
|
|
2016
Q3 | $2.76M | Buy |
44,479
+11,848
| +36% | +$838K | ﹤0.01% | 2355 |
|
|
2016
Q2 | $1.84M | Buy |
32,631
+16,042
| +97% | +$975K | ﹤0.01% | 2534 |
|
|
2016
Q1 | $1.06K | Buy |
16,589
+804
| +5% | +$65K | ﹤0.01% | 2848 |
|
|
2015
Q4 | $2.22M | Buy |
15,785
+277
| +2% | +$37.6K | ﹤0.01% | 2409 |
|
|
2015
Q3 | $1.5M | Buy |
+15,508
| New | +$1.85M | ﹤0.01% | 2626 |
|
Geode Capital Management's KDNY Position: Q3 2023 in Review
Geode Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,060,417 shares — an estimated $40.7M sold.
Geode Capital Management first reported a position in KDNY in Q3 2015 and held it in 32 quarters. The position peaked at $40.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Geode Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Geode Capital Management sold 1,060,417 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $40.7M.
- Geode Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 32 quarters.
- Geode Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $40.7M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.